Blog
Bem-vindo ao nosso blog - seu novo canal de informações para notícias, lançamento de produtos, artigos científicos, estudos de caso e muito mais.
View all blogs:
Croda Pharma launches a new bioprocessing solution for shear stress in mammalian cell culture
Croda Pharma has announced the launch of Super Refined™ Poloxamer 188, an innovative bioprocessing solution developed to meet the increasing demands of biopharmaceutical development.
Announcing Avanti Research - a Croda brand
Avanti Polar Lipids, a global leader in lipids, has announced its renewed offering for researchers and its transformation to Avanti Research.
Croda joins CGT Catapult consortium to improve AAV formulation
The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation.
.png?w=768&la=pt-BR&focalpointcrop=1&xratio=0&yratio=0&hash=BB57B2026E644DBD4EF0F9B9B21EC836)
Veterinary vaccines - solutions for an ongoing challenge...
Growth in the veterinary pharmaceutical industry continues to be driven by increasing pet ownership globally and the rising demand for veterinary vaccines to prevent the risk of zoonotic diseases in...
EXCLUSIVE WHITEPAPER: Next-generation Triton™ X-100 replacements for pharmaceutical bioprocessing
Triton™ X-100 (tert-octyl phenyl ethoxylate) is used extensively in the manufacture of biologics, plasma-derived products and cell and gene therapies (CGTs). This non-ionic detergent is used because...
.png?w=768&la=pt-BR&focalpointcrop=1&xratio=0&yratio=0&hash=42621CCA5FF23C30DE30F874E5A9606C)
QbD Formulation Development
Formulation development is a pivotal stage in the life cycle of a therapeutic drug product, it can be the make or break of it. The goal of formulation development is to convert active substance (drug...
Croda Foundation announces it has sustainably improved the lives of 22.8 million people – exceeding its 2030 target.
Croda Foundation announces it has sustainably improved the lives of 22.8 million people –exceeding its 2030 target.
Partnership agreement between Croda and AAHI to drive innovation in vaccine development
19 March 2024: Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce today the signing of a partnership agreement around innovation and development...
Specializing in specific enhancement technologies
Croda Pharma specializes in four technologies aimed at improving bioavailability and solubility. Find out more!
Concerns about Triton™ X-100 have been an ongoing discussion across multiple regulatory authorities around the world
Triton™ X-100, a non-ionic surfactant with a hydrophilic polyethylene oxide chain and a hydrophobic aromatic group1, has found widespread use in the biopharmaceutical industry with applications...
“Close the Care Gap” – World Cancer Day 2024
We are proud to continue supporting the development of cancer treatments, and on this World Cancer Day, recognise the importance of innovation and science to cure and treat those diagnosed. Together,...
Spotlight on Kritika Bajaj
Highlighting the scientists and teams who are involved in our latest product launch, Virodex™, replacements for Triton™ X-100, we sat down with Kritika Bajaj and asked her about her involvement around...
Innovative lipids for your nucleic acid delivery research
Lipid-based therapeutic delivery systems have been evolving for many years. From delivering naked mRNA, to using liposomes, and now lipid nanoparticles,
Introducing our Adjuvant Systems Platform
Introducing our Adjuvant Systems platform. Leveraging a history of developing adjuvants since 1939, our scientists deliver high performance adjuvants to meet your vaccine needs today.
Introducing our Small Molecule Delivery platform
Our offering for Small Molecule Delivery focuses on tackling your formulation challenges and enhancing drug delivery through our high purity Super Refined™ excipients. Over the years, enhancing...
The future of mRNA delivery: Advancements in engineering lipid nanoparticles for enhanced intracellular delivery through inhalation
Messenger RNA (mRNA) has played a crucial role in recent vaccine developments and is at the forefront of much current medical research. Traditionally. the delivery of mRNA systemically via lipid...
Lipid Leaders: Dennis Christensen
In this Lipid Leaders interview, we get insight from Croda Pharma's own Global Head of R&D - Adjuvant Systems, Dennis Christensen, PhD. Keep reading to learn more about adjuvants and the role they...
A abordagem da Croda para a Iniciativa de Mercados Sustentáveis para metas de sustentabilidade de fornecedores
A recente declaração pública do Grupo de Trabalho para Sistemas de Saúde da Iniciativa para os Mercados Sustentáveis apelou para que as cadeias de abastecimento de cuidados de saúde adotassem práticas...
Sustentabilidade em vacinas: Descarbonização de uma de nossas principais instalações
Sustentabilidade frequentemente é definida como o atendimento das necessidades das gerações atuais sem comprometer a capacidade das gerações futuras de atenderem às suas próprias necessidades. Este é...
A powerful match - celebrating three years of Croda Pharma and Avanti
Today marks three years since we acquired Avanti Polar Lipids. During the COVID-19 pandemic, it became clear that the combination of Avanti's lipid expertise and our manufacturing scale-up capability...